dc.contributor.author | Kurt, Bulent | |
dc.contributor.author | Yalcin, Serap | |
dc.contributor.author | Alagoz, Engin | |
dc.contributor.author | Karslioglu, Yildirim | |
dc.contributor.author | Yigit, Nuri | |
dc.contributor.author | Gunal, Armagan | |
dc.contributor.author | Deveci, M. Salih | |
dc.date.accessioned | 2019-11-24T20:58:13Z | |
dc.date.available | 2019-11-24T20:58:13Z | |
dc.date.issued | 2012 | |
dc.identifier.issn | 1046-3976 | |
dc.identifier.issn | 1559-0097 | |
dc.identifier.uri | https://dx.doi.org/10.1007/s12022-012-9218-7 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12513/3021 | |
dc.description | WOS: 000307518400001 | en_US |
dc.description | PubMed ID: 22767446 | en_US |
dc.description.abstract | It has been shown that BRAF(V600E) mutation in papillary thyroid carcinomas (PTC) is associated both with pathogenesis and poor prognosis. In this study, we aimed to investigate the relationship of the BRAF(V600E) mutation and the established prognostic factors in a cohort of Turkish patients with PTC. Forty-six cases of papillary thyroid carcinoma have been evaluated for the presence of BRAF(V600E) mutation. BRAF(V600E) has been examined by restriction fragment length polymorphism. BRAF(V600E) mutation status has been compared with well-known histopathological and clinical prognostic parameters such as invasion of thyroid capsule, extrathyroidal extension, and the presence of lymph node and/or distant metastasis. We have found that BRAF(V600E) mutation was present in the majority of our cases (40/46). Considering the stage of the disease, five of the negative cases were in stage 1 while the remaining one was in stage 2. Only one BRAF(V600E) negative case has shown extrathyroidal extension and lymph node metastasis. All four patients with distant metastasis had BRAF(V600E) mutation. Statistical analyses revealed that there are no significant relationship between the BRAF(V600E) mutation and the established prognostic factors. We found a relatively higher BRAF(V600E) mutation rate in classical type PTC than in other similar studies. We think that the limited number of our cases may either weaken or mask some potentially important relationship between BRAF(V600E) mutation and the established prognostic factors. | en_US |
dc.description.sponsorship | Scientific and Technological Research Council of Turkey (TUBITAK)Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK) [19816] | en_US |
dc.description.sponsorship | The authors would like to thank to Scientific and Technological Research Council of Turkey (TUBITAK) for their support (Grant No: 19816). We also would like to express our sincere appreciation to FAVOR (FMF Arthritis Vasculitis and Orphan Diseases Research) laboratories at Gulhane Military Medical Academy, Institute of Health Sciences for their supports in conducting the experiments and invaluable guidance for the preparation of the manuscript. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | HUMANA PRESS INC | en_US |
dc.relation.isversionof | 10.1007/s12022-012-9218-7 | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Papillary thyroid carcinoma | en_US |
dc.subject | BRAF(V600E) | en_US |
dc.subject | Prognosis | en_US |
dc.subject | Diagnosis | en_US |
dc.title | The Relationship of the BRAF(V600E) Mutation and the Established Prognostic Factors in Papillary Thyroid Carcinomas | en_US |
dc.type | article | en_US |
dc.relation.journal | ENDOCRINE PATHOLOGY | en_US |
dc.contributor.department | Kırşehir Ahi Evran Üniversitesi, Kaman Meslek Yüksekokulu | en_US |
dc.identifier.volume | 23 | en_US |
dc.identifier.issue | 3 | en_US |
dc.identifier.startpage | 135 | en_US |
dc.identifier.endpage | 140 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |